Linda Billett

home / authors / linda-billett

Linda Billett is a CMC director of global regulatory affairs at AstraZeneca (Macclesfield).

Articles

Drug Substance Starting Material Selection

Graham Illing;Robert Timko;Linda Billett

December 2nd 2008

The authors review the current regulatory framework for the selection of drug substance starting materials.

Latest Updated Articles

Buy, Sell, Hold: Cell and Gene Therapy

Published: October 11th 2024 | Updated: October 18th 2024

Buy, Sell, Hold: Cell and Gene Therapy - Part 1

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Published: September 10th 2024 | Updated: September 18th 2024

CPHI Milan Announces 2024 CPHI Pharma Award Finalists

Published: August 21st 2024 | Updated: December 27th 2024

Pharmaceutical Technology Editorial Advisory Board

Leveraging Integrated Patient-Centric Innovations When Developing Today’s Biologics

Published: November 25th 2024 | Updated: December 27th 2024

Leveraging Integrated Patient-Centric Innovations When Developing Today’s Biologics

Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development

Published: December 20th 2024 | Updated: December 27th 2024

Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development

Europa Perspectives: Helping to Navigate the Regulatory System

Published: February 23rd 2024 | Updated: December 27th 2024

Europa Perspectives: Helping to Navigate the Regulatory System

Editorial Advisory Board

Do Not Sell My Personal Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.